Anti-factor Xa level monitoring of low-molecular-weight heparin for prevention of venous thromboembolism in critically ill patients (AXaLPE): protocol of a randomised, open-label controlled clinical trial

INTRODUCTION: Whether and when to monitor the amount of anti-factor Xa (aFXa) activity in critically ill patients with complex diseases to prevent venous thromboembolism (VTE) remain unclear. This study is a randomised controlled trial to investigate the effect of aFXa level monitoring on reducing V...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chunmei, Ning, Ya-chan, Song, Li-po, Li, Pei-juan, Wang, Feng-hua, Ding, Meng-xi, Jiang, Li, Wang, Meiping, Pei, Qian-Qian, Hu, Shi-min, Wang, Haibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Intensive Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603447/
https://www.ncbi.nlm.nih.gov/pubmed/37880168
http://dx.doi.org/10.1136/bmjopen-2022-069742

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603447/
https://www.ncbi.nlm.nih.gov/pubmed/37880168
http://dx.doi.org/10.1136/bmjopen-2022-069742

Ejemplares similares